For unclassified renal cell carcinoma cases, it is advisable to perform next-generation sequencing (NGS) and ALK testing, as these analyses may identify actionable mutations or alterations that can guide targeted therapeutic strategies and improve clinical outcomes. The gene discussed is ALK; the disease is renal cell carcinoma.